|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
December 13, 2024
Date of Report (Date of Earliest Event Reported)

The Chemours Company
(Exact Name of Registrant as Specified in Its Charter)
Delaware |
|
001-36794 |
|
46-4845564 |
(State or Other Jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
Of Incorporation) |
|
File Number) |
|
Identification No.) |
1007 Market Street
Wilmington, Delaware 19801
(Address of principal executive offices)
Registrant’s telephone number, including area code: (302) 773-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
|
Trading Symbol(s) |
|
Name of Exchange on Which Registered |
Common Stock ($0.01 par value) |
|
CC |
|
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company |
|
☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |
|
☐ |
|
|
Item 1.01 |
Entry into a Material Definitive Agreement. |
On December 13, 2024, The Chemours Company (the “Company”) entered into Amendment No. 2 (the “Second Amendment”) among the Company, certain subsidiaries of the Company, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “Administrative Agent”), which amends the Second Amended and Restated Credit Agreement, dated as of August 18, 2023, among the Company, the lenders from time to time party thereto and the Administrative Agent (as amended by Amendment No. 1, dated as of November 29, 2024 and as further amended, supplemented or otherwise modified from time to time prior to December 13, 2024, the “Existing Credit Agreement”). The Second Amendment reduces the applicable margin in respect of the Company’s €415,000,000 Euro denominated term loan facility (the “Tranche B-3 Euro Term Loan Facility”) from adjusted EURIBOR + 4.00% to adjusted EURIBOR + 3.25%. There are no changes to the maturity of the Term B-3 Euro Term Loan Facility following this repricing, and all other terms are substantially unchanged. Capitalized terms used in this Item 1.01 but not otherwise defined herein have the meanings assigned to them in the Existing Credit Agreement as amended.
The foregoing description of the Second Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Second Amendment which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 2.03 |
Creation of a Direct Financial Obligation or an Obligation under Off-Balance Sheet Arrangement of a Registrant. |
The information set forth in Item 1.01 is incorporated herein by reference.
Item 7.01 |
Regulation FD Disclosure. |
On December 13, 2024, the Company issued a press release announcing entry into the Second Amendment. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit 10.1 |
|
Exhibit 99.1 |
Press release dated as of December 13, 2024 issued by the Chemours Company
|
Exhibit 104 |
Cover Page Interactive Data File (formatted as Inline XBRL)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THE CHEMOURS COMPANY |
||
|
||
By: |
|
/s/ Shane Hostetter |
|
|
Shane Hostetter |
|
|
Senior Vice President, Chief Financial Officer |
Date: |
|
December 13, 2024 |
EXHIBIT 10.1
AMENDMENT NO. 2 dated as of December 13, 2024 (this “Amendment”), among THE CHEMOURS COMPANY, a Delaware corporation (the “Borrower”), the other LOAN PARTIES party hereto, the LENDERS party hereto and JPMORGAN CHASE BANK, N.A. (“JPMorgan”), as administrative agent (in such capacity, the “Administrative Agent”), to the Second Amended and Restated Credit Agreement dated as of August 18, 2023 (as amended, supplemented or otherwise modified from time to time prior to the Amendment Effective Date (as defined below), the “Existing Credit Agreement”), among the Borrower, the lenders and issuing banks party thereto and the Administrative Agent. Capitalized terms used in this Amendment but not otherwise defined shall have the meanings assigned to such terms in the Existing Credit Agreement, except as otherwise expressly set forth herein.
WHEREAS pursuant to the Existing Credit Agreement, the Lenders and the Issuing Banks have agreed to extend credit to the Borrower on the terms and subject to the conditions set forth therein;
WHEREAS the Borrower intends to reduce the Applicable Rate applicable to the Tranche B-3 Euro Term Loans and to effect certain other modifications to the Existing Credit Agreement as set forth herein;
WHEREAS each Tranche B-3 Euro Term Lender (each, an “Existing Term Lender”) holding outstanding Tranche B-3 Euro Term Loans immediately prior to the Amendment Effective Date (“Existing Term Loans”) that executes and delivers a signature page to this Amendment (each, a “Consenting Term Lender”) will have agreed to the terms of this Amendment upon the effectiveness of this Amendment on the Amendment Effective Date. Each Existing Term Lender that is not a Consenting Term Lender (each, a “Non-Consenting Term Lender”) will be deemed not to have agreed to this Amendment as it applies to the Existing Term Loans held by such Non-Consenting Term Lender and will be subject to the mandatory assignment provisions of Section 9.02(c) of the Existing Credit Agreement upon the effectiveness of this Amendment on the Amendment Effective Date solely with respect to its Existing Term Loans (it being understood that the interests, rights and obligations of the Non-Consenting Term Lenders and of the Consenting Term Lenders that elect “Assign and Reallocation Consent Option” on their signature page hereto (collectively, the “Assigning Term Lenders”) under the Existing Credit Agreement and each other Loan Document with respect to the Existing Term Loans will be assumed by JPMorgan in accordance with Section 1 hereof and will be subsequently assigned by JPMorgan in accordance with Section 9.02(c) of the Existing Credit Agreement (JPMorgan, in its capacity as the assignee of the Existing Term Loans of the Assigning Term Lenders, the “New Term Lender”));
WHEREAS on the Amendment Effective Date, the Borrower shall have paid to the Administrative Agent, for the ratable benefit of the Existing Term Lenders, all accrued and unpaid interest to, but not including, the Amendment Effective Date, with respect to the Existing Term Loans; and
WHEREAS the undersigned Lenders are willing to amend such provisions of the Existing Credit Agreement, in each case on the terms and subject to the conditions set forth herein;
NOW, THEREFORE, in consideration of the mutual agreements herein contained and other good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, and subject to the conditions set forth herein, the parties hereto hereby agree as follows:
EXHIBIT 10.1
““Amendment No. 2” means Amendment No. 2 to this Agreement, dated as of December 13, 2024.
EXHIBIT 10.1
“Amendment No. 2 Effective Date” means the Amendment Effective Date as defined in Amendment No. 2, which date (for the avoidance of doubt) will be December 13, 2024.”;
“(b) with respect to any Loan that is a Tranche B-3 Euro Term Loan, (i) prior to the Amendment No. 2 Effective Date, 4.00% per annum, and (ii) on and after the Amendment No. 2 Effective Date, 3.25% per annum”; and
“(or, solely with respect to (A) the Tranche B-3 US$ Term Borrowings, the date that is six months after the Amendment No. 1 Effective Date and (B) the Tranche B-3 Euro Term Borrowings, the date that is six months after the Amendment No. 2 Effective Date)”.
EXHIBIT 10.1
EXHIBIT 10.1
Notwithstanding the foregoing, the requirements of this Section 5 shall be deemed to be satisfied if the documentation delivered by or on behalf of the Loan Parties pursuant to Section 5 of Amendment No. 1 addresses the requirements of this Section 5 (and the Loan Parties shall not be required to deliver duplicative documentation pursuant to this Section 5).
EXHIBIT 10.1
[Signature Pages Follow]
IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their respective authorized officers as of the day and year first written above.
EXHIBIT 10.1
THE CHEMOURS COMPANY |
|
By /s/ Shane Hostetter |
|
|
|
|
Name: Shane Hostetter |
|
Title: Chief Financial Officer |
THE CHEMOURS COMPANY FC, LLC |
|
By /s/ Shane Hostetter |
|
|
|
|
Name: Shane Hostetter |
|
Title: Chief Financial Officer |
FT CHEMICAL, INC. |
|
By /s/ Shane Hostetter |
|
|
|
|
Name: Shane Hostetter |
|
Title: Chief Financial Officer |
FIRST CHEMICAL HOLDINGS, LLC |
|
By /s/ Shane Hostetter |
|
|
|
|
Name: Shane Hostetter |
|
Title: Chief Financial Officer |
|
FIRST CHEMICAL TEXAS, L.P., BY FT CHEMICAL, INC., ITS GENERAL PARTNER |
|
By /s/ Shane Hostetter |
|
|
|
|
Name: Shane Hostetter |
|
Title: Chief Financial Officer |
EXHIBIT 10.1
JPMORGAN CHASE BANK, N.A., INDIVIDUALLY AS A LENDER, AS THE NEW TERM LENDER AND AS THE ADMINISTRATIVE AGENT, |
|
By /s/ James Shender |
|
|
|
|
Name: James Shender |
|
Title: Executive Director |
|
|
|
|
|
|
EXHIBIT 99.1

The Chemours Company Announces Completion of Euro denominated Term Loan Repricing
Wilmington, Del., December 13, 2024 -- The Chemours Company (Chemours) (NYSE: CC) today announced the successful repricing of its Tranche B-3 Euro denominated Term Loan under its senior secured term loan facility due in August 2028.
The Second Amendment reduces the applicable margin in respect of the Company’s €415,000,000 Euro denominated term loan facility, the “Tranche B-3 Euro Term Loan Facility,” from adjusted EURIBOR + 4.00% to adjusted EURIBOR + 3.25%. There are no changes to the maturity of the Term B-3 Euro Term Loan Facility following this repricing, and all other terms are substantially unchanged.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers’ biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 6,100 employees and 28 manufacturing sites and serves approximately 2,700 customers in approximately 110 countries.
For more information, we invite you to visit chemours.com or follow us on X (formerly Twitter) @Chemours or LinkedIn.
1
EXHIBIT 99.1

Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words “believe,” “expect,” “will,” “anticipate,” “plan,” “estimate,” “target,” “project” and similar expressions, among others, generally identify “forward-looking statements,” which speak only as of the date such statements were made. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond Chemours’ control. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in Chemours’ filings with the U.S. Securities and Exchange Commission, including in Chemours’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, and in Chemours’ Annual Report on Form 10-K for the year ended December 31, 2023. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.
CONTACTS:
INVESTORS
Brandon Ontjes
VP, Head of Strategy & Investor Relations
+1.302.773.3300
investor@chemours.com
NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
media@chemours.com
2